Stefano Caruso - Concepedia

Author

Stefano Caruso

Also Known As

Antonino Catalano, Beatriz Mínguez, Caruso, S., Caruso, Stefano, Marco Capacci, S Caruso, S. Caruso, S., Caruso, Stefano Caruso, Stefano, Caruso

164

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Inserm Université Paris Cité Centre de Recherche des Cordeliers Sorbonne Université Assistance Publique – Hôpitaux de Paris

About

Stefano Caruso is an author at Inserm specializing in medicine, tumor biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	29	2.4K
2	Engineering	3	3	424
3	Health Sciences	2	2	402
4	Natural Sciences	2	2	123
5	Public Health	1	1	47

Stefano Caruso

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation Jean‐Charles Nault, Gabrielle Couchy, Charles Balabaud, Gastroenterology Tumor BiologyHepatologyMalignant DiseaseMedicineHistopathology	2016	377
Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis Aveline Filliol, Yoshinobu Saito, Ajay Nair, Nature Developmental BiologyHepatologyLiver PhysiologyLiver CancerLiver	2022	307
Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma Camille Péneau, Sandrine Imbeaud, Tiziana La Bella, Gut	2021	214
Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma Jean‐Charles Nault, Yoann Martin, Stefano Caruso, Hepatology EngineeringPathologyTumor BiologyClinical ImpactOncology	2019	207
Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling Debanjan Dhar, Laura Antonucci, Hayato Nakagawa, Cancer Cell OncologyMedicineLiver PhysiologyPathologyCell Death	2018	198
Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response Stefano Caruso, Anna-Line Calatayud, Jill Pilet, Gastroenterology	2019	171
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Yann Vano, Réza Elaidi, Mostefa Bennamoun, The Lancet Oncology UrologyOncologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2022	128
Dual Targeting of Histone Methyltransferase G9a and DNA‐Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma Marina Bárcena‐Varela, Stefano Caruso, Susana Llerena, Hepatology	2018	122
Adeno-associated virus in the liver: natural history and consequences in tumour development Tiziana La Bella, Sandrine Imbeaud, Camille Péneau, Gut	2019	120
Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival Lisa Quetel, Clément Meiller, Jean‐Baptiste Assié, Molecular Oncology Molecular HeterogeneityMalignant Pleural MesotheliomaMpm HeterogeneityGliomaTumor Heterogeneity	2020	112

Page 1